Alnylam Pharmaceuticals Revenue 2006-2019 | ALNY

Alnylam Pharmaceuticals annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Alnylam Pharmaceuticals revenue for the quarter ending December 31, 2019 was $0.072B, a 240.8% increase year-over-year.
  • Alnylam Pharmaceuticals revenue for the twelve months ending December 31, 2019 was $0.220B, a 193.36% increase year-over-year.
  • Alnylam Pharmaceuticals annual revenue for 2019 was $0.22B, a 193.36% increase from 2018.
  • Alnylam Pharmaceuticals annual revenue for 2018 was $0.075B, a 16.69% decline from 2017.
  • Alnylam Pharmaceuticals annual revenue for 2017 was $0.09B, a 90.66% increase from 2016.
Alnylam Pharmaceuticals Annual Revenue
(Millions of US $)
2019 $220
2018 $75
2017 $90
2016 $47
2015 $41
2014 $51
2013 $47
2012 $67
2011 $83
2010 $100
2009 $101
2008 $96
2007 $51
2006 $27
2005 $6
Alnylam Pharmaceuticals Quarterly Revenue
(Millions of US $)
Q4 2019 $72
Q3 2019 $70
Q2 2019 $45
Q1 2019 $33
Q4 2018 $21
Q3 2018 $2
Q2 2018 $30
Q1 2018 $22
Q4 2017 $38
Q3 2017 $17
Q2 2017 $16
Q1 2017 $19
Q4 2016 $17
Q3 2016 $14
Q2 2016 $9
Q1 2016 $7
Q4 2015 $8
Q3 2015 $6
Q2 2015 $9
Q1 2015 $19
Q4 2014 $24
Q3 2014 $11
Q2 2014 $7
Q1 2014 $8
Q4 2013 $11
Q3 2013 $9
Q2 2013 $9
Q1 2013 $19
Q4 2012 $8
Q3 2012 $17
Q2 2012 $21
Q1 2012 $21
Q4 2011 $20
Q3 2011 $21
Q2 2011 $21
Q1 2011 $21
Q4 2010 $21
Q3 2010 $28
Q2 2010 $27
Q1 2010 $25
Q4 2009 $27
Q3 2009 $24
Q2 2009 $25
Q1 2009 $25
Q4 2008 $24
Q3 2008 $26
Q2 2008 $24
Q1 2008 $22
Q4 2007 $18
Q3 2007 $16
Q2 2007 $9
Q1 2007 $7
Q4 2006 $7
Q3 2006 $8
Q2 2006 $6
Q1 2006 $6
Q4 2005 $2
Q3 2005 $1
Q2 2005 $1
Q1 2005 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $14.752B $0.220B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $131.403B 15.02
CSL (CSLLY) Australia $100.847B 0.00
Gilead Sciences (GILD) United States $88.181B 11.35
Vertex Pharmaceuticals (VRTX) United States $63.855B 57.95
Biogen (BIIB) United States $58.609B 10.01
Regeneron Pharmaceuticals (REGN) United States $44.354B 18.79
Illumina (ILMN) United States $43.503B 44.98
Alexion Pharmaceuticals (ALXN) United States $22.835B 10.62
Seattle Genetics (SGEN) United States $20.154B 0.00
SINO PHARMACEUT (SBMFF) Hong Kong, SAR China $19.260B 0.00
Incyte (INCY) United States $17.535B 37.62
BioMarin Pharmaceutical (BMRN) United States $17.093B 0.00
Genmab (GNMSF) Denmark $15.432B 49.63
Galapagos (GLPG) Belgium $15.022B 38.71
Exact Sciences (EXAS) United States $12.981B 0.00
Bio-Rad Laboratories (BIO.B) United States $12.088B 56.48
BeiGene (BGNE) Cayman Islands $10.354B 0.00
Sarepta Therapeutics (SRPT) United States $9.242B 0.00
QIAGEN (QGEN) Netherlands $8.430B 25.96
Guardant Health (GH) United States $8.340B 0.00
Bio-Techne Corp (TECH) United States $7.902B 54.08
BioNTech SE (BNTX) Germany $7.320B 0.00
ACADIA Pharmaceuticals (ACAD) United States $6.951B 0.00
Ascendis Pharma (ASND) Denmark $6.774B 0.00
Horizon Therapeutics Public (HZNP) Ireland $6.649B 16.91
Exelixis (EXEL) United States $6.408B 18.03
Amarin (AMRN) Ireland $6.405B 0.00
Reata Pharmaceuticals (RETA) United States $6.391B 0.00
ARGENX SE-ADR (ARGX) Netherlands $6.140B 0.00
Moderna (MRNA) United States $6.135B 0.00
Repligen (RGEN) United States $5.107B 93.44
Acceleron Pharma (XLRN) United States $5.017B 0.00
China Biologic Products (CBPO) China $4.603B 25.93
Bluebird Bio (BLUE) United States $4.460B 0.00
Adaptive Biotechnologies (ADPT) United States $4.247B 0.00
MorphoSys AG (MOR) Germany $3.917B 0.00
Mirati Therapeutics (MRTX) United States $3.725B 0.00
Blueprint Medicines (BPMC) United States $3.654B 0.00
Immunomedics (IMMU) United States $3.492B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.438B 0.00
Zai Lab (ZLAB) China $3.435B 0.00
Emergent Biosolutions (EBS) United States $3.404B 23.81
NeoGenomics (NEO) United States $3.392B 180.50
Momenta Pharmaceuticals (MNTA) United States $3.347B 0.00
Genmab (GMAB) Denmark $3.247B 12.74
CRISPR Therapeutics AG (CRSP) Switzerland $3.227B 54.67
Halozyme Therapeutics (HALO) United States $3.199B 0.00
Alkermes (ALKS) Ireland $3.194B 253.00
Intercept Pharmaceuticals (ICPT) United States $3.109B 0.00
MyoKardia (MYOK) United States $3.076B 0.00
Insmed (INSM) United States $2.792B 0.00
Amicus Therapeutics (FOLD) United States $2.747B 0.00
UniQure (QURE) Netherlands $2.645B 0.00
Arena Pharmaceuticals (ARNA) United States $2.640B 6.14
Denali Therapeutics (DNLI) United States $2.348B 0.00
Fate Therapeutics (FATE) United States $2.339B 0.00
Epizyme (EPZM) United States $2.266B 0.00
RA PHARMCTL INC (RARX) United States $2.201B 0.00
Principia Biopharma (PRNB) United States $2.154B 0.00
Alector (ALEC) United States $2.100B 0.00
REGENXBIO (RGNX) United States $1.939B 0.00
Ligand Pharmaceuticals (LGND) United States $1.769B 51.66
Zymeworks (ZYME) Canada $1.758B 0.00
Akcea Therapeutics (AKCA) United States $1.707B 0.00
Arvinas (ARVN) United States $1.703B 0.00
Coherus BioSciences (CHRS) United States $1.580B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $1.475B 0.00
Myriad Genetics (MYGN) United States $1.465B 25.85
Zealand Pharma (ZLDPF) Denmark $1.461B 0.00
Zealand Pharma (ZEAL) Denmark $1.459B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.425B 0.00
Intra-Cellular Therapies (ITCI) United States $1.369B 0.00
Editas Medicine (EDIT) United States $1.269B 0.00
Revance Therapeutics (RVNC) United States $1.254B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.194B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $1.187B 0.00
Twist Bioscience (TWST) United States $1.172B 0.00
Athenex (ATNX) United States $1.142B 0.00
PHARMA MAR SA (PHMMF) Spain $1.024B 0.00
Adverum Biotechnologies (ADVM) United States $0.959B 0.00
Mesoblast (MESO) Australia $0.922B 0.00
Pharming Group (PHGUF) Netherlands $0.908B 0.00
DBV Technologies S.A (DBVT) France $0.906B 0.00
Cytokineticsorporated (CYTK) United States $0.903B 0.00
Sangamo Therapeutics (SGMO) United States $0.863B 0.00
Vericel (VCEL) United States $0.859B 320.25
Codexis (CDXS) United States $0.819B 0.00
Cellectis S.A (CLLS) France $0.799B 0.00
Arcus Biosciences (RCUS) United States $0.794B 0.00
Heska (HSKA) United States $0.790B 201.94
Intrexon (PGEN) United States $0.769B 0.00
ANI Pharmaceuticals (ANIP) United States $0.743B 12.67
Retrophin (RTRX) United States $0.742B 0.00
Cara Therapeutics (CARA) United States $0.690B 0.00
GENFIT S.A (GNFT) France $0.676B 0.00
Kadmon Holdings (KDMN) United States $0.658B 0.00
Intellia Therapeutics (NTLA) United States $0.655B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.650B 5.47
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.640B 0.00
UROGEN PHARMA (URGN) United States $0.633B 0.00
Anika Therapeutics (ANIK) United States $0.610B 20.85
Clovis Oncology (CLVS) United States $0.603B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.597B 0.00
Bellus Health (BLU) Canada $0.590B 0.00
AC Immune SA (ACIU) Switzerland $0.568B 13.14
NantKwest (NK) United States $0.566B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.552B 0.00
Puma Biotechnology (PBYI) United States $0.530B 0.00
Compugen (CGEN) Israel $0.513B 0.00
Aquinox Pharmaceuticals (NLTX) United States $0.499B 0.00
BioDelivery Sciences (BDSI) United States $0.498B 0.00
Agenus (AGEN) United States $0.484B 0.00
Prothena (PRTA) Ireland $0.474B 0.00
Sinovac Biotech (SVA) China $0.460B 0.00
Cue Biopharma (CUE) United States $0.456B 0.00
Merus (MRUS) Netherlands $0.445B 0.00
AnaptysBio (ANAB) United States $0.438B 0.00
Sorrento Therapeutics (SRNE) United States $0.426B 0.00
Mersana Therapeutics (MRSN) United States $0.422B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.421B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.420B 0.00
Dynavax Technologies (DVAX) United States $0.409B 0.00
Precision BioSciences (DTIL) United States $0.407B 0.00
Avid Bioservices (CDMO) United States $0.405B 0.00
Kindred Biosciences (KIN) United States $0.401B 0.00
PDL BioPharma (PDLI) United States $0.397B 9.94
Adaptimmune Therapeutics (ADAP) United Kingdom $0.393B 0.00
Inovio Pharmaceuticals (INO) United States $0.380B 0.00
Gritstone Oncology (GRTS) United States $0.374B 0.00
Stemline Therapeutics (STML) United States $0.342B 0.00
CytomX Therapeutics (CTMX) United States $0.332B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.322B 0.00
MannKind (MNKD) United States $0.322B 0.00
Cellular Biomedicine (CBMG) United States $0.322B 0.00
Albireo Pharma (ALBO) United States $0.316B 0.00
Syros Pharmaceuticals (SYRS) United States $0.312B 0.00
WAVE Life Sciences (WVE) Singapore $0.305B 0.00
Starpharma Holdings (SPHRY) Australia $0.302B 0.00
OSMOTICA PHARM (OSMT) United States $0.301B 0.00
Aduro Biotech (ADRO) United States $0.294B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.286B 1.98
Syndax Pharmaceuticals (SNDX) United States $0.284B 0.00
Bicycle Therapeutics (BCYC) United Kingdom $0.272B 0.00
POXEL SA FRANCE (PXXLF) France $0.271B 0.00
Kamada (KMDA) Israel $0.268B 11.17
Seres Therapeutics (MCRB) United States $0.267B 0.00
VBI Vaccines (VBIV) United States $0.266B 0.00
Sutro Biopharma (STRO) United States $0.266B 0.00
IVERIC Bio (ISEE) United States $0.254B 0.00
Geron (GERN) United States $0.254B 0.00
Biofrontera AG (BFRA) Germany $0.253B 0.00
Novavax (NVAX) United States $0.248B 0.00
Protagonist Therapeutics (PTGX) United States $0.246B 0.00
XOMA (XOMA) United States $0.242B 0.00
Prometic Life Sciences (LMNL) Canada $0.241B 0.00
Kala Pharmaceuticals (KALA) United States $0.239B 0.00
ChromaDex (CDXC) United States $0.239B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.228B 0.00
Alcobra (ARCT) United States $0.226B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.225B 0.00
ADMA Biologics Inc (ADMA) United States $0.218B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.217B 0.00
Cerecor (CERC) United States $0.212B 0.00
Abeona Therapeutics (ABEO) United States $0.207B 0.00
Theratechnologies (THTX) Canada $0.207B 0.00
Affimed (AFMD) Germany $0.206B 0.00
Arbutus Biopharma (ABUS) Canada $0.202B 0.00
TELA Bio (TELA) United States $0.201B 0.00
Athersys (ATHX) United States $0.201B 0.00
Five Prime Therapeutics (FPRX) United States $0.195B 0.00
Fortress Biotech (FBIO) United States $0.192B 0.00
Exicure (XCUR) United States $0.185B 0.00
Spero Therapeutics (SPRO) United States $0.184B 0.00
VTv Therapeutics (VTVT) United States $0.181B 0.00
Strongbridge Biopharma (SBBP) United States $0.177B 4.72
Northwest Biotherapeutics (NWBO) United States $0.171B 0.00
Verastem (VSTM) United States $0.162B 0.00
Selecta Biosciences (SELB) United States $0.159B 0.00
Aptinyx (APTX) United States $0.158B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.157B 0.00
Windtree Therapeutics (WINT) United States $0.156B 0.00
Dyadic (DYAI) United States $0.149B 0.00
Celyad SA (CYAD) Belgium $0.145B 0.00
Liquidia Technologies (LQDA) United States $0.144B 0.00
PHASEBIO PHARMA (PHAS) United States $0.141B 0.00
Antibe Therapeutics (ATBPF) Canada $0.136B 0.00
Newron Pharmaceuticals SpA (NWPHF) Italy $0.134B 0.00
ARAVIVE, INC (ARAV) United States $0.131B 0.00
Arsanis (XFOR) United States $0.130B 0.00
Menlo Therapeutics (MNLO) United States $0.127B 0.00
OvaScience (MLND) United States $0.121B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.118B 0.00
Clearside Biomedical (CLSD) United States $0.118B 0.00
Prima BioMed (IMMP) Australia $0.110B 0.00
Enzo Biochem (ENZ) United States $0.107B 0.00
Proteostasis Therapeutics (PTI) United States $0.102B 0.00
Happiness Biotech Group (HAPP) China $0.101B 0.00
Applied Genetic Technologies (AGTC) United States $0.097B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.097B 0.00
AIT Therapeutics (XAIR) United States $0.093B 0.00
Emmaus Life Sciences (EMMA) United States $0.092B 0.00
Synlogic (SYBX) United States $0.091B 0.00
Checkpoint Therapeutics (CKPT) United States $0.091B 0.00
Vaccinex (VCNX) United States $0.090B 0.00
SESEN BIO, INC (SESN) United States $0.089B 0.00
Adocia (ADOCY) France $0.086B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.086B 0.00
Catalyst Biosciences (CBIO) United States $0.086B 0.00
Pluristem Therapeutics (PSTI) Israel $0.080B 0.00
Orgenesis (ORGS) United States $0.074B 4.74
Acorda Therapeutics (ACOR) United States $0.073B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.070B 0.00
Trevena (TRVN) United States $0.070B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.068B 0.00
DiaMedica Therapeutics (DMAC) United States $0.067B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.066B 0.00
Soligenix (SNGX) United States $0.065B 0.00
NewLink Genetics (NLNK) United States $0.060B 0.00
Advaxis (ADXS) United States $0.059B 0.00
China Health Industries Holdings (CHHE) China $0.056B 16.98
CollPlant Holdings (CLGN) Israel $0.052B 0.00
Vascular Biogenics (VBLT) Israel $0.052B 0.00
Celldex Therapeutics (CLDX) United States $0.050B 0.00
Idera Pharmaceuticals (IDRA) United States $0.049B 0.00
Curis (CRIS) United States $0.047B 0.00
Organovo Holdings (ONVO) United States $0.046B 0.00
TOCAGEN INC (TOCA) United States $0.045B 0.00
Evogene (EVGN) Israel $0.040B 0.00
AquaBounty Technologies (AQB) United States $0.039B 0.00
Entera Bio (ENTX) Israel $0.037B 0.00
VistaGen Therapeutics (VTGN) United States $0.033B 0.00
Alimera Sciences (ALIM) United States $0.033B 0.00
Stellar Biotechnologies (EDSA) Canada $0.032B 0.00
Celsion (CLSN) United States $0.031B 0.00
Pulmatrix (PULM) United States $0.031B 0.00
BioCardia (BCDA) United States $0.030B 0.00
Bionano Genomics (BNGO) United States $0.029B 0.00
Oncobiologics (OTLK) United States $0.029B 0.00
Aerpio Pharmaceuticals (ARPO) United States $0.028B 0.00
Signal Genetics (MGEN) United States $0.026B 0.00
VIVUS (VVUS) United States $0.026B 0.00
Novogen (KZIA) Australia $0.025B 0.00
Unum Therapeutics (UMRX) United States $0.023B 0.00
Cleveland BioLabs (CBLI) United States $0.022B 0.00
Aptevo Therapeutics (APVO) United States $0.022B 0.00
AEterna Zentaris (AEZS) United States $0.020B 0.00
Titan Pharmaceuticals (TTNP) United States $0.016B 0.00
Genetic Technologies (GENE) Australia $0.016B 0.00
Aytu Bioscience (AYTU) United States $0.016B 0.00
IMMURON (IMRN) Australia $0.014B 0.00
Cesca Therapeutics (THMO) United States $0.014B 0.00
TrovaGene (TROV) United States $0.013B 0.00
Cyclacel Pharmaceuticals (CYCC) United States $0.012B 0.00
TRACON Pharmaceuticals (TCON) United States $0.012B 0.00
MYOS RENS Technology (MYOS) United States $0.011B 0.00
Prana Biotechnology (ATHE) Australia $0.010B 0.00
Benitec Biopharma (BNTC) Australia $0.007B 0.00
Neuralstem (SNCA) United States $0.004B 0.00